TSE:HLS FY2025 EPS Forecast Lifted by Clarus Securities

Key Points

• Clarus Securities has increased its FY2025 earnings estimate for HLS Therapeutics from ($0.45) to ($0.40) per share, while also projecting FY2026 earnings at ($0.18) EPS.
• Raymond James Financial upgraded HLS Therapeutics from a "hold" to a "moderate buy" rating and raised the price target from C$5.00 to C$6.00.
• The consensus rating for HLS Therapeutics remains a "Hold" with an average target price of C$5.00, reflecting cautious investor sentiment.

HLS Therapeutics Inc. (TSE:HLS - Free Report) - Stock analysts at Clarus Securities lifted their FY2025 earnings estimates for HLS Therapeutics in a report issued on Thursday, August 21st. Clarus Securities analyst G. Ulybyshev now anticipates that the company will earn ($0.40) per share for the year, up from their prior forecast of ($0.45). The consensus estimate for HLS Therapeutics' current full-year earnings is ($0.12) per share. Clarus Securities also issued estimates for HLS Therapeutics' FY2026 earnings at ($0.18) EPS.

Separately, Raymond James Financial upgraded shares of HLS Therapeutics from a "hold" rating to a "moderate buy" rating and upped their price target for the stock from C$5.00 to C$6.00 in a research report on Thursday. One investment analyst has rated the stock with a Hold rating, According to MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of C$5.00.

HLS Therapeutics Stock Performance

HLS opened at C$5.22 on Monday. The firm has a market cap of C$116.13 million, a P/E ratio of -5.23 and a beta of 1.07. HLS Therapeutics has a 1-year low of C$3.00 and a 1-year high of C$5.48. The company has a 50 day simple moving average of C$4.96 and a two-hundred day simple moving average of C$4.61. The company has a debt-to-equity ratio of 86.50, a current ratio of 1.56 and a quick ratio of 1.01.

HLS Therapeutics Company Profile

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.